ResearchMoz

Ovarian Cancer Market Research Reports & Industry Analysis

Ovarian Cancer Market Research Reports & Industry Analysis Ovarian Cancer

Browse reports in Ovarian Cancer

Displaying 1 to 17 (of 17 records)
Pages: « Last  1   
Avastin (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Avastin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on...
$2000
Gemzar (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Gemzar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes information on...
$2000
Farletuzumab (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Farletuzumab sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes...
$2000
Votrient (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Votrient sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Ovarian...
$2000
Opaxio (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Opaxio sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Ovarian...
$2000
Doxil/Caelyx (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
Vargatef (Ovarian Cancer) Analysis and Forecats to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020 provides Vargatef sales forecasts for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Ovarian Cancer...
$2000
Karenitecin (Ovarian Cancer) Analysis and Forecast to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Karenitecin sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes...
$2000
Paclical (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, "Paclical (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Paclical sales estimates for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on...
$2000
Paclitaxel (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Paclitaxel sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
Cisplatin (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, "Cisplatin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Cisplatin sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
AMG 386 (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, "AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020 provides AMG 386 sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Ovarian...
$2000
Carboplatin (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, "Carboplatin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Carboplatin sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
Yondelis (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Yondelis sales forecasts for EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Ovarian...
$2000
Recentin (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Recentin (Ovarian Cancer) Analysis and Forecasts to 2020 provides Recentin sales estimates for US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Ovarian Cancer...
$2000
Olaparib (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Olaparib (Ovarian Cancer) Analysis and Forecasts to 2020 provides Olaparib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on...
$2000
EC145 (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, EC145 (Ovarian Cancer) - Analysis and Forecasts to 2020 provides EC145 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on Ovarian Cancer...
$2000
 
Displaying 1 to 17 (of 17 records)
Pages: « Last  1